文献速递心力衰竭与心肌病心律失常血脂与心血管预防

免疫检查点抑制剂心肌与肌肉毒性:法国全国性研究

Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study.
PubMed 文献 · Eur Heart J · 2026-01-01

心肌炎与肌炎发生率0.3%-0.6%,约13%-23%共存;发生ICI心肌肌肉毒性者1个月病死率20.3%,是影响死亡率的最强因素。

要点

  • ICI相关心肌肌肉毒性6个月发生率0.7%-0.9%,胸腺癌患者可高达7.1%。
  • 主要风险因素包括胸腺肿瘤、黑色素瘤、胸腺疾病史、重症肌无力史、联合ICI及高龄。
  • ICI心肌肌肉毒性发生后1个月病死率20.3%,严重心律失常、心衰和呼吸衰竭增加死亡风险。

核心结论

  • 法国全国真实世界研究明确了ICI相关心肌肌肉毒性的发生率和风险因素,并发现该毒性是ICI启动后影响死亡率的最强因素。

主要发现

  • 6个月时ICI心肌肌肉毒性发生率窄定义0.7%、宽定义0.9%,胸腺癌患者高达7.1%。
  • ICI心肌炎和肌炎发生率0.3%-0.6%,约13%-23%病例两者共存。
  • 宽定义下主要风险因素:胸腺肿瘤sHR 12.94(95%CI 5.22-32.03)、黑色素瘤2.41(2.06-2.83)、其他皮肤癌2.07(1.55-2.76)、胸腺疾病史5.61(2.66-11.86)、重症肌无力史2.50(1.45-4.32)、联合ICI 2.44(1.99-2.98)、年龄>85岁较<45岁1.79(1.24-2.59)。
  • ICI心肌肌肉毒性发生是ICI启动后影响死亡率的最强因素,1个月HR 3.51(95%CI 3.17-3.89),超过转移状态(1.55 [1.52-1.58])。
  • ICI心肌肌肉毒性患者1个月病死率20.3%,合并严重心律失常(风险比1.64 [1.03-2.61])、心力衰竭(1.49 [1.06-2.07])和呼吸衰竭(1.50 [1.05-2.15])时病死率进一步升高。

临床怎么用

  • 对接受ICI治疗的患者,尤其胸腺癌、黑色素瘤、有胸腺疾病或重症肌无力史、联合ICI及高龄者,应警惕心肌肌肉毒性。
  • 发生ICI心肌肌肉毒性后需密切监测严重心律失常、心力衰竭和呼吸衰竭,因其与1个月高病死率相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Immune checkpoint inhibitor (ICI)-induced (cardio)-myotoxicities, including myocarditis and myositis, are uncommon but frequently severe adverse drug reactions seen in cancer patients. Real-life ICI myotoxicity incidence estimates span from limited-size cohorts, with risk factors and prognosticators poorly established, as well as their impact on survival. METHODS: This retrospective French National Health Data System cohort study included all adult patients starting ICI between 1 January 2012 and 30 September 2022. A 'narrow' and a 'broad' code combination (based on International Classification of Diseases-10 codes) were used for studied outcomes. The primary outcome was the occurrence of myotoxicities and secondary outcomes of myocarditis and myositis. Risk factors of these outcomes at 6 months were identified with Fine and Gray multivariable models, considering demographics, comorbidities, co-treatments, and cancer. Immune checkpoint inhibitor myotoxicity (as a time-dependent variable) association with overall survival was tested using Cox models. Risk factors of 1- and 3-month letality in ICI myotoxicity cases were assessed by multivariable logistic regression. RESULTS: In 172 363 ICI-treated adult patients, incidence of ICI myotoxicities at 6 months ranged between 0.7% and 0.9% (narrow or broad definitions, respectively), with up to 7.1% in patients with thymic cancer. Immune checkpoint inhibitor myocarditis and ICI myositis incidence ranged between 0.3% and 0.6%, co-occurring in ∼13%-23% of cases. The main risk factors for developing ICI myotoxicities (broad, n = 1520) were thymic tumour (sub-distribution hazard ratio [sHR] 12.94, 95% confidence interval [CI] 5.22-32.03), melanoma (2.41 [2.06-2.83]) and other skin cancers (2.07 [1.55-2.76]), history of thymic disorders (5.61 [2.66-11.86]), history of myasthenia gravis (2.50 [1.45-4.32]), combination of ICI (2.44 [1.99-2.98]), and age > 85 [1.79 [1.24-2.59] vs <45 years. Immune checkpoint inhibitor myotoxicity occurrence was the factor impacting most mortality after ICI start (HR 3.51 [95% CI 3.17-3.89] at 1 month), over metastatic status (1.55 [1.52-1.58]). In ICI myotoxicity patients, 1-month fatality was 20.3% and increased if severe arrhythmia (risk ratio 1.64 [95% CI 1.03-2.61]), heart failure (1.49 [1.06-2.07]), and respiratory failure (1.50 [1.05-2.15]) were reported. Additionally, results were consistent with secondary outcomes, using narrow and broad definitions. CONCLUSIONS: This pharmaco-epidemiological study assessed >170 000 French patients treated by ICI in real life, establishing the incidence and identifying risk factors of developing ICI myotoxicities, with severity surrogates associated with fatality.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Salem JE, Ajrouche A, Rozes A, et al. Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study. Eur Heart J. 2026. PMID: 40884033. doi:10.1093/eurheartj/ehaf682

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。